BriaCell receives Nasdaq notice for failing $35M minimum MVLS requirement

BriaCell Therapeutics Corp.

Received Nasdaq letter on July 3, 2024, for MVLS below $35M for 33 consecutive business days.
Has until December 30, 2024 (180-day compliance period) to regain compliance.
To regain compliance, MVLS must close at $35M+ for at least 10 consecutive business days.
Failure could lead to delisting, with appeal rights to a Nasdaq Hearings Panel.
Listing continues pending compliance; no immediate impact on trading.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.